BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

EDEN Bioscience (EDEN) Mails Definitive Proxy Materials for Special Meeting of Shareholders Scheduled for May 20, 2009


4/3/2009 11:52:55 AM

WOODINVILLE, WA--(Marketwire - April 03, 2009) - Eden Bioscience Corporation (NASDAQ: EDEN) today announced that it has filed with the Securities and Exchange Commission ("SEC"), and commenced mailing to shareholders, its definitive proxy statement for the special meeting of shareholders to vote for approval of the voluntary dissolution and liquidation of the Company. The definitive proxy statement is being mailed to all Company shareholders of record as of March 23, 2009. The special meeting of shareholders will be held at 9 a.m., Pacific time, on May 20, 2009, at the Country Inn & Suites By Carlson located at 19333 North Creek Parkway in Bothell, Washington.

On December 5, 2008, the Company announced that its Board of Directors determined, in its best business judgment after consideration of available strategic options, that it is in the best interests of the Company and its shareholders to liquidate the Company's assets and to dissolve the Company and had approved a plan of complete dissolution and liquidation of the Company (the "Plan"), subject to shareholder approval. The Board of Directors unanimously recommends that the Company's shareholders vote for approval of the Plan.

IMPORTANT ADDITIONAL INFORMATION FILED WITH THE SEC

This press release is for informational purposes only. It is neither a solicitation of a proxy, an offer to purchase, nor a solicitation of an offer to sell shares of Eden Bioscience Corporation. In connection with the proposed Plan, the Company filed with the SEC a definitive proxy statement and other relevant materials. THE COMPANY'S SHAREHOLDERS ARE URGED TO READ THE DEFINITIVE PROXY STATEMENT AND THE OTHER RELEVANT MATERIALS FILED WITH THE SEC BECAUSE THEY CONTAIN IMPORTANT INFORMATION ABOUT THE COMPANY AND THE PLAN. Shareholders may obtain a free copy of the definitive proxy statement and the other relevant materials, and any other documents filed by the Company with the SEC, at the SEC's web site at http://www.sec.gov. In addition, on April 2, 2009, the Company commenced mailing of the definitive proxy statement to shareholders of record on March 23, 2009, the record date for the special meeting. A free copy of the definitive proxy statement and other documents filed with the SEC by the Company may also be obtained by directing a written request to: Eden Bioscience Corporation, Attn: Secretary, 14522 NE North Woodinville Way, Suite 202B, Woodinville, Washington 98072, or accessing the "About Us -- Investor Information" section of the Company's website at http://www.edenbio.com.

The Company and its executive officer and directors may be deemed to be participants in the solicitation of proxies from the Company's shareholders with respect to the proposed Plan. Information regarding their direct or indirect interests, by security holdings or otherwise, in the solicitation is included in the definitive proxy statement filed by the Company with the SEC.


CONTACT
Nathaniel T. Brown
Eden Bioscience Corporation
14522 NE North Woodinville Way, Suite 202B
Woodinville, WA 98072
425-984-2120
Fax: 425-806-7400



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES